Market news

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]

Treace Medical outlook: revenue declines, Lapiplasty losing share, margins compressing, and EBITDA delayed. Click for more on TMCI stock.

Motley Fool Press Release.

Detailed price information for Treace Medical Concepts Inc (TMCI-Q) from The Globe and Mail including charting and trades.

Treace Medical Concepts (TMCI) has an average rating of hold and mean price target of $5.17, accordi

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Generated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025. Reported second quarter 2026 net loss of

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the second quarter 2026 before the start of trading on Friday, August 7, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Inves